Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

12,953 total articles

YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations

YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations

YD Bio Limited announced that its U.S. clinical laboratory affiliate, EG BioMed US Inc., has obtained clinical lab licenses in Rhode Island and Pennsylvania, expanding its U.S. lab footprint to 46 states plus DC and Guam. This expansion enhances patient access to early cancer detection tests based on DNA methylation and supports the company's trans…

Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.

Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.

Vivani Medical's wholly owned subsidiary Cortigent, Inc. is set to merge with ClearOne, Inc., a Nasdaq-listed company, resulting in a new entity named Cortigent Holdings, Inc. trading under the ticker CRGT. The transaction includes a financing round between $10M and $15M to fund development of Cortigent's neurostimulation brain-computer interface t…

ZenaTech to Showcase Drone as a Service Growth and ZenaDrone Defense Solutions at Series of U.S. and Global Investor and Defense Events

ZenaTech to Showcase Drone as a Service Growth and ZenaDrone Defense Solutions at Series of U.S. and Global Investor and Defense Events

ZenaTech, Inc., a Nasdaq-listed AI drone technology company, announced its participation in a series of investor and defense industry events across the U.S. and globally. The company aims to showcase its growth in Drone as a Service (DaaS), highlight its subsidiary ZenaDrone's advanced AI-powered drone defense solutions, and build relationships wit…

Hudbay Receives Regulatory Approval to Further Increase Mill Throughput at its Constancia Mine in Peru

Hudbay Receives Regulatory Approval to Further Increase Mill Throughput at its Constancia Mine in Peru

Hudbay Minerals Inc. announced that it has obtained approval from Peru's SENACE to amend its environmental permit, allowing an increase in the Constancia mine's mill throughput capacity from 31 million to 34 million tonnes of ore annually. This amendment marks the fifth permit change and supports operational optimization, extended mine life, and im…

Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

Revolution Medicines announced encouraging Phase 1/2 clinical trial results of its investigational oral RAS(ON) G12D-selective inhibitor zoldonrasib combined with chemotherapy and daraxonrasib for treating patients with metastatic pancreatic ductal adenocarcinoma harboring RAS G12D mutations. The data demonstrated manageable safety profiles and str…

VisionWave Appoints Former UK Member of Parliament Ben Everitt’s Stratonex Defence Technologies as Strategic UK and European Commercialization Partner

VisionWave Appoints Former UK Member of Parliament Ben Everitt’s Stratonex Defence Technologies as Strategic UK and European Commercialization Partner

VisionWave Holdings, Inc. announced a strategic Distributor Agreement with UK-based Stratonex Defence Technologies, co-founded by former UK MP Ben Everitt, to commercialize and integrate VisionWave's advanced defense technologies across the United Kingdom, Europe, and other agreed markets. The partnership aims to enhance VisionWave’s reach in defen…

Swarmer, Tekmara and Florida International University Explore Autonomous Drone Swarms for Coastal Restoration and Environmental Monitoring

Swarmer, Tekmara and Florida International University Explore Autonomous Drone Swarms for Coastal Restoration and Environmental Monitoring

Swarmer, Inc. (NASDAQ: SWMR), a drone autonomy software firm known for its combat drone coordination, announced a collaboration with Tekmara and Florida International University to explore using autonomous drone swarms for large-scale environmental monitoring and restoration of coastal habitats such as mangroves and oyster reefs. The partnership wi…

Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial

Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial

Polyrizon Ltd. announced successful completion of the biocompatibility evaluation program for its proprietary NASARIX™ Allergy Blocker nasal spray, meeting all predefined safety criteria under international standards. This significant milestone supports the safety profile of NASARIX™ and paves the way for moving towards human clinical trials and po…

Kartoon Studios Adopts Limited Duration Stockholder Rights Plan

Kartoon Studios Adopts Limited Duration Stockholder Rights Plan

Kartoon Studios has adopted a limited duration stockholder rights plan, distributing rights to existing shareholders as a precautionary protective measure against potential unsolicited takeover attempts. The plan is not a response to any specific offer but aims to safeguard shareholder value. The company continues to focus on growth through its str…

Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM

Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM

BridgeBio Pharma announces publication of post-hoc analyses demonstrating that acoramidis, their oral TTR stabilizer approved as Attruby®, provides early and sustained kidney-protective benefits in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). These effects resemble those seen with ACE inhibitors, ARBs, and SGLT2 inhibitors and coin…

Caliber Advances Real Estate Fund Tokenization Strategy with Chainlink’s Compliance and Distribution Infrastructure

Caliber Advances Real Estate Fund Tokenization Strategy with Chainlink’s Compliance and Distribution Infrastructure

Caliber, a Nasdaq-listed real estate-focused asset manager, advances its real estate fund tokenization strategy by integrating Chainlink's oracle platform, including the Automated Compliance Engine (ACE), to enhance compliance, investor onboarding, and distribution across regulated markets. This initiative aims to improve liquidity, valuation trans…

StablecoinX Launches StablecoinX Harness: Stablecoin Orchestration Platform to Accelerate USDe Adoption

StablecoinX Launches StablecoinX Harness: Stablecoin Orchestration Platform to Accelerate USDe Adoption

StablecoinX Inc., a Nasdaq-listed stablecoin infrastructure company focused on the Ethena digital dollar ecosystem, announced the launch of StablecoinX Harness, a middleware platform that simplifies integrations with major stablecoins, allowing businesses and financial institutions to accept, hold, and transfer stablecoins seamlessly. This innovati…

IREN Appoints Chief Product Officer and Chief Development Officer

IREN Appoints Chief Product Officer and Chief Development Officer

IREN Limited has appointed Kambiz Aghili as Chief Product Officer and Michael Nudelman as Chief Development Officer, bolstering its leadership team to accelerate growth in its AI Cloud platform. Aghili brings extensive cloud product strategy experience from Oracle Cloud Infrastructure, while Nudelman offers two decades in data center development an…

Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026

Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026

Tenax Therapeutics announced that topline results from its Phase 3 LEVEL clinical trial evaluating oral levosimendan in patients with pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) will be presented at the ESC Congress 2026 in August. The trial enrolled over 230 patients across the US and Canada and is power…